Prestige Consumer Healthcare to Acquire Breathe Right and Other Brands for $1.045 Billion, Boosting Portfolio and Revenue
Summary
Prestige Consumer Healthcare announced a definitive agreement to acquire the Breathe Right® brand and other OTC products for $1.045 billion in cash, a move expected to be immediately accretive to financials and expand its brand portfolio.
Key Events
-
Major Acquisition Announced
Prestige Brands, Inc., a wholly-owned subsidiary, entered into an Asset Purchase Agreement to acquire a portfolio of over-the-counter consumer health products, including Breathe Right® and other brands, from Foundation Consumer Brands, LLC.
-
Significant Purchase Price
The acquisition is valued at $1.045 billion in cash, or approximately $900 million net of anticipated tax benefits.
-
Strong Financial Contribution
The acquired portfolio generated approximately $200 million in revenue and $95 million in EBITDA over the twelve months ended December 31, 2025.
-
Accretive to Financials
The transaction is expected to be immediately accretive to Prestige's revenue, gross margins, EBITDA margins, earnings per share, and free cash flow.
Analysis
Prestige Consumer Healthcare's agreement to acquire the Breathe Right® brand and other OTC products for $1.045 billion is a highly significant strategic move. This acquisition, representing a substantial portion of the company's market capitalization, is expected to be immediately accretive to revenue, margins, EPS, and free cash flow. The addition of Breathe Right®, a leading brand in the 'better breathing' category, expands Prestige's portfolio into a new, attractive segment with international reach. While the transaction will initially increase the company's net leverage to approximately 4.0x, management has outlined a clear path to deleveraging to below 3.0x by fiscal 2028, supported by strong free cash flow generation. This strategic expansion, announced while the stock is trading near its 52-week low, could be a catalyst for investor re-evaluation, demonstrating management's commitment to growth and value creation through disciplined M&A.
At the time of this filing, PBH was trading at $60.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $57.25 to $89.37. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.